Skip to main content
Craig McDonald, MD, Physical Medicine/Rehab, Sacramento, CA, UC Davis Medical Center

CraigMichelMcDonaldMD

Physical Medicine/Rehab Sacramento, CA

Neuromuscular Medicine, Pediatric Rehabilitation Medicine

Professor, Physical Medicine & Rehabilitation, UC, Davis School of Medicine

Dr. McDonald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. McDonald's full profile

Already have an account?

Education & Training

  • University of Washington/Seattle Children's Hospital
    University of Washington/Seattle Children's HospitalChief Residency, Pediatric Physical Medicine & Rehabilitation, 1991 - 1992
  • University of Washington
    University of WashingtonResidency, Physical Medicine and Rehabilitation, 1989 - 1992
  • University of Washington Graduate School
    University of Washington Graduate SchoolMaster's, Rehabilitation Medicine, 1989 - 1991
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1988 - 1989
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 1987
  • Stanford University
    Stanford UniversityA.B., Human Biology, 1978 - 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1988 - 2025
  • American Board of Physical Medicine and Rehabilitation Physical Medicine & Rehabilitation
  • American Board of Physical Medicine and Rehabilitation Neuromuscular Medicine
  • American Board of Physical Medicine and Rehabilitation Pediatric Rehabilitation Medicine

Awards, Honors, & Recognition

  • Carolyn Braddom Ritzler Research Award from the Association of Academic Physiatrists. Association of Academic Physiatrists, 2019
  • Clinical Research Forum’s Top Ten Clinical Research Achievement Awards which honor outstanding accomplishments in clinical research. (Top 20) Clinical Research Forum, 2018-2019
  • Castle Connolly Regional Top Doctor” for 2018 by a Peer Review Survey of regional physicians Castle Connolly Medical Ltd., 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM  
    Klingels K, Mayhew AG, Mazzone ES, Duong T, Decostre V, Werlauff U, Vroom E, Mercuri E, Goemans NM; Upper Limb Clinical Outcome Group, Med Child Neurol, 1/26/2016
  • Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy  
    Heberer K, Fowler E, Staudt L, Sienko S, Buckon CE, Bagley A, Sison-Williamson M, McDonald CM, Sussman MD, Gait Posture, 1/24/2016
  • Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study  
    Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, C..., Ann Clin Transl Neurol, 1/21/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Meta-analyses of ataluren in patients with nonsense mutation Duchenne muscular dystrophy.
    Campbell C, Muntoni C, Mercuri E, Luo X, Elfring G, Kroger H, Riebling P, Ong T, Spiegel G, Peltz SW, McDonald C, 45th CNS Annual Meeting, Vancouver, BC, Canada, 1/26/2016
  • Results of North Star Ambulatory Assessments in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD).
    Muntoni F, Luo X, Elfring G, Kroger H, Riebling P, Ong T, Spiegel R, Peltz S, McDonald C, 45th CNS Annual Meeting, Vancouver, BC, Canada, 1/26/2016
  • Effect of Tadalafil, a Phosphodiesterase Type 5 Inhibitor, on Ambulatory Decline in Boys with Duchenne Muscular Dystrophy: Top-Line Results of a Phase III, Randomized,...
    Victor RG, Finkel R, Sweeney HL, McDonald CM, Byrne B, Vandenborne K, Miceli C, Eagle M, Goemans N, Furlong P, Landry J, Elashoff R, and Cox D, 2016 MDA Clinic Directors Meeting, Denver, CO, 1/20/2016
  • Join now to see all

Lectures

  • 6-Minute Walk Test (6MWT) in Duchenne Muscular Dystrophy. 
    Taormina, Italy
  • The Impact of Steroids for Young Children with Duchenne muscular dystrophy. 
    Orlando, FL - 1/28/2016
  • Epicatechin for Treatment of Dystrophinopathy. 
    Orlando, FL - 1/27/2016
  • Join now to see all

Other

  • FDA Advisory Committee on Eteplirsen as an exon skipping treatment for for exon 51 skipping amenable patients with in Duchenne muscular dystrophy. 
    McDonald CM, Expert Testimony for Sarepta Therapeutics
    Washington, DC - 1/26/2016
  • Translarna (ataluren) for the treatment of nonsense mutation DMD. 
    McDonald CM, Parent Project Muscular Dystrophy (PPMD) National Webinar
    1/1/2016
  • Understanding clinical endpoints in Duchenne Muscular Dystrophy. 
    McDonald CM, PTC webinar "ACT DMD Clinical Trial Results."
    1/15/2015
  • Join now to see all

Press Mentions

  • Cell Treatment Slows Disease in Duchenne Muscular Dystrophy Patients
    Cell Treatment Slows Disease in Duchenne Muscular Dystrophy PatientsMarch 11th, 2022

Grant Support

  • Ninds Network For Excellence In Neuroscience: Clinical Research Site At UC DavisNational Institute Of Neurological Disorders And Stroke2011
  • Clinically Meaningful Outcomes For Duchenne Muscular Dystrophy Therapeutic TrialsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • Biomarker Discovery And Validation In A Duchenne Dystrophy Natural History StudyNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
  • Child Mobility: Role Of Strength, Body Fat &Energy COSTEunice Kennedy Shriver National Institute Of Child Health &Human Development1997–2000

Professional Memberships

Hospital Affiliations